期刊文献+

TIRC7在慢性髓系白血病患者单核细胞中的表达

Expression of TIRC7 in mononuclear cells in patients with chronic myeloid leukemia
原文传递
导出
摘要 目的探讨T细胞免疫应答cDNA7(TIRC7)在慢性髓系白血病(CML)患者单核细胞(MNC)中的表达水平。方法收集24例CML患者(CML组)及6例健康志愿者(对照组)的新鲜骨髓或外周血,采用琼脂糖凝胶电泳及实时荧光定量PCR法检测TIRC7基因在MNC中的表达水平。结果应用TIRC7引物可扩增出大小约210bp的片段,与理论值相符。CML组TIRC7扩增条带亮度较弱,而对照组TIRC7条带明亮。CML组TIRC7相对表达量为0.085(0.032,0.197),低于对照组的0.960(0.715,2.027)(P<0.01)。结论 TIRC7在CML患者MNC中的表达水平较低,可能在CML的发生、发展中起重要作用。 Objective To investigate the expression of T-cell immune response cDNA 7(TIRC7)in mononuclear cells(MNC)of patients with chronic myeloid leukemia(CML).Methods The fresh bone marrow or peripheral blood was collected from 24 CML patients(group CML)and 6 healthy people(group C).The expression of TIRC7 in MNC was detected by agarose gel electrophoresis and real-time quantitative PCR.Results The 210 bp fragment was amplified by TIRC7 primer and coincided with theoretical value.The stripe in group CML was weaker and that in group C was brighter.The relative expression of TIRC7 was lower in group CML than that in group C(P〈0.01).Conclusion The expression of TIRC7 is lower in MNC of CML patients,which may be related to the development of CML.
作者 尹玲玲 朱锋 赵恺 徐开林 YIN Lingling, ZHU Feng, ZHAO Kai, et al(Department of Hematology, Affiliated Hospital, Xuzhou Medical University, Xuzhou 221002, CHIN)
出处 《江苏医药》 CAS 2018年第3期253-255,共3页 Jiangsu Medical Journal
基金 国家自然科学基金(81200376) 江苏省"六大人才高峰"资助项目(2012-WSN-082)
关键词 T细胞免疫应答互补脱氧核糖核酸7 慢性髓系白血病 单核细胞 T-cell immune response complementary deoxyribonucleic acid 7 Chronic myeloidleukemia Mononuclear cell
  • 相关文献

参考文献3

二级参考文献29

  • 1盛立霞,邱国强,谢晓宝,顾伟英,王志林,吴浩清.两种白血病细胞抗原负载DC的体外诱导特异性CTL应答的比较[J].细胞与分子免疫学杂志,2005,21(2):205-209. 被引量:12
  • 2叶红英.自身免疫性甲状腺疾病的T淋巴细胞亚群异常[J].国外学者来访报告,1996,16(3):46-48. 被引量:5
  • 3Smppia L, Calabrese G, Pelia R, et al. p53 loss and point mutations are associated with suppression of apoptosis and progression of CAVIL into myeloid blastic crisis[J]. Cancer Genet Cytogenet, 1997, 98(1): 190-207.
  • 4Sheng KC, Pietresz GA, Wright MD, et al. Dendritic cells:activation and maturation-applications for cancer immunotherapy[J]. Curr Med Chem, 2005, 12(15): 1783-1880.
  • 5Zhang YL, LiJ, Mo HY, et al. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways[J]. Mol Cancer, 2010, 10(9): 4.
  • 6Shen LS, Wang j, Shen DF, et al. CD4(+)CD25(+)CD127(Iow/-) regulatory T cells express Foxp3 and suppress effector T cell prolif eradon and contribute to gastric cancers progressionS]. Clin Imrnunol, 2009, 131(1): 109-118.
  • 7Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive Function of CD4+CD25+ regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine[J]. Blood, 2005, 106(6): 2018-2025.
  • 8Wang X, ZhengJ, LiuJ, et al. Increased population of CD4(+)CD25 (high), regulatory T cells with their higher apoptotic and proliferating stares in peripheral blood of acute myeloid leukemia patients[J]. EurJ Haematol, 2005, 75(6):468-476.
  • 9Li Y, TangJP, Fu CY, et al. The use of albendazole and diammonium glycyrrhizinate in the treatment of eosinophilic meIfingitis in mice infected with Angiostrongylus cantonensis, j Helminthol, 2011, 13: 1-11.
  • 10Jensen LM. Myelopoiesis in myelodyspasia evaluated by multiparameter flow cytometry. Leuk lymphoma, 1995, 20(1-2):17-25.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部